HC Wainwright Has Negative Outlook for MIRM FY2027 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Stock analysts at HC Wainwright cut their FY2027 earnings per share (EPS) estimates for Mirum Pharmaceuticals in a report released on Monday, January 26th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.04 per share for the year, down from their prior forecast of $0.86. HC Wainwright currently has a “Buy” rating and a $130.00 target price on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ FY2028 earnings at $1.29 EPS and FY2029 earnings at $3.57 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.15. The company had revenue of $133.01 million for the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The firm’s revenue for the quarter was up 47.1% compared to the same quarter last year. During the same period last year, the company earned ($0.30) EPS.

A number of other equities research analysts also recently commented on the company. Leerink Partners set a $100.00 price objective on Mirum Pharmaceuticals in a research report on Wednesday, December 10th. Raymond James Financial restated a “strong-buy” rating and issued a $110.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. JMP Securities set a $95.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 5th. Finally, Wall Street Zen raised shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $104.92.

Mirum Pharmaceuticals Stock Up 2.1%

MIRM stock opened at $102.92 on Wednesday. The company has a 50 day moving average price of $79.65 and a two-hundred day moving average price of $71.96. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. The stock has a market capitalization of $5.29 billion, a P/E ratio of -119.67 and a beta of 0.48. Mirum Pharmaceuticals has a one year low of $36.88 and a one year high of $103.81.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Eventide Asset Management LLC raised its holdings in shares of Mirum Pharmaceuticals by 4.4% during the 2nd quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock valued at $134,224,000 after buying an additional 110,485 shares during the period. Vanguard Group Inc. boosted its holdings in Mirum Pharmaceuticals by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock worth $205,065,000 after acquiring an additional 50,720 shares during the period. Geode Capital Management LLC grew its position in Mirum Pharmaceuticals by 6.8% in the second quarter. Geode Capital Management LLC now owns 1,029,616 shares of the company’s stock valued at $52,405,000 after acquiring an additional 65,951 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Mirum Pharmaceuticals by 566.8% during the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after purchasing an additional 672,118 shares during the period. Finally, Boone Capital Management LLC lifted its position in shares of Mirum Pharmaceuticals by 6.3% during the second quarter. Boone Capital Management LLC now owns 641,448 shares of the company’s stock worth $32,643,000 after purchasing an additional 38,130 shares in the last quarter.

Insider Activity

In related news, CEO Christopher Peetz sold 7,098 shares of the company’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total transaction of $662,456.34. Following the completion of the sale, the chief executive officer directly owned 163,733 shares of the company’s stock, valued at approximately $15,281,200.89. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Peter Radovich sold 3,143 shares of the stock in a transaction on Monday, January 26th. The shares were sold at an average price of $96.19, for a total value of $302,325.17. Following the completion of the sale, the chief operating officer owned 23,286 shares of the company’s stock, valued at approximately $2,239,880.34. This represents a 11.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 32,429 shares of company stock valued at $3,039,396 over the last quarter. 14.36% of the stock is owned by insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.